Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus IOPAMIDOL 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus IOPAMIDOL 200.
DIONOSIL AQUEOUS vs IOPAMIDOL-200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL AQUEOUS contains propyliodone, a radiocontrast agent that absorbs X-rays, providing visualization of bronchial structures. It acts by coating the bronchial mucosa and filling the airways, allowing radiographic imaging.
Iopamidol is a nonionic iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It does not have a pharmacological effect but provides radiographic opacity.
Intra-articular injection: 2-3 mL of 1% solution (20-30 mg) per joint; maximum 4 joints per session. Intravenous: 2-4 mL of 20% solution (400-800 mg) diluted in 20 mL water, administered slowly over 5-10 minutes, for peripheral angiography.
Intravascular: 50-150 mL (75-225 mg iodine/kg) IV; frequency depends on procedure, usually single dose. Intrathecal: 5-15 mL (200 mg iodine/mL) injected into subarachnoid space.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment.
Terminal half-life: 2 hours (normal renal function); prolonged to 8-48 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for >95% of elimination; <5% is eliminated via biliary/fecal routes.
Renal: >95% unchanged via glomerular filtration within 24 hours; biliary/fecal: <1%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent